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Telomere erosion and fusion play an important role in the pathology of many common 
human malignancies including CLL.1,2 Previous studies in CLL have shown that short 
telomeres defined on the basis of the median value or receiver operating characteristic 
(ROC) analysis are associated with unmutated IGHV genes, poor risk genomic 
abnormalities, genomic complexity and high expression of CD38, CD49d, and ZAP70 
whereas long telomeres are associated with increasing IGHV mutational load, isolated 
deletion of 13q and low CD49d expression. In addition, in predominantly diagnostic or 
mixed patient cohorts, telomere length (TL) predicts time to first treatment and/or overall 
survival (OS) in multivariate analyses of models incorporating established biomarkers. 3-7 
However uncertainties about the most clinically relevant measure of telomere length, the 
optimal choice of assay, the need for assay standardisation and the lack of published data on 
the prognostic value of TL in patients entered into randomised trials have hindered the 
implementation of TL measurement into routine clinical practice. We have attempted to 
address these issues by measuring telomere length using monochrome multiplex Q-PCR 
(MMQ-PCR) in 384 patients at randomisation into the UK LRF CLL4 phase 3 
chemotherapy trial (Table S1), of whom 111 samples were also screened by single telomere 
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length analysis (STELA). Telomere length and established biomarkers were measured as 
previously described. 8-13
The mean TL assessed by MMQ-PCR in 384 cases was 3.57 TLU (Telomere Length Units, 
range 0.61-19.05). For 111 FC patients analysed by both MMQ-PCR and STELA, we 
showed an excellent correlation between these two TL measurements (Spearman correlation 
0.80) (Fig S1), permitting the calibration of the mean TLU to a mean absolute TL of 3.39kb 
(range 1.93-11.06kb, median 2.92kb [Inter quartile range: 2.58, 3.60]) for our cohort. All 
subsequent analyses were based on data derived from MMQ-PCR expressed in Kb rather 
than TLU. TL was found to be significantly associated with IGHV mutation status, ZAP70 
and CD38 expression, serum beta-2 microglobulin, TP53 abnormality, 11q deletion, 
genomic complexity, ATM and SF3B1 mutation but not trisomy 12 or NOTCH1 mutation 
(Table S2).
Increasing TL, entered as a continuous variable, was associated with a significant reduction 
in risk of a PFS event (HR=0.89, 95%CI: 0.85-0.93, p<0.001) and longer OS (HR=0.84, 
95%CI: 0.80-0.89, p<0.001) (Table S3). To determine a single TL cut-off value with 
maximum prognostic power, we employed recursive partitioning and identified the 75th and 
80th percentile for PFS (HR: 2.42, p<0.001) and OS (HR: 3.17, p<0.001), respectively (Fig 
S2), demonstrating that identifying cases with the longest telomeres is key to maximising the 
prognostic value of these data. We then performed Kaplan-Meier analysis and generated a 
categorical variable with three groups for telomere length - short (<50 percentile), 
intermediate (50-75 percentile) and long (>75 percentile) (Fig 1 and S3). The range for the 
mean TL in the short group was 1.93-2.92 kb (median: 2.58 kb), in the intermediate group, 
2.91-3.57 kb (median: 3.14 kb), and in the long group, 3.64-11.06 kb (median: 4.81 kb). 
Interestingly, we have previously shown that telomere fusions were never detected when the 
mean telomere length exceeded 3.81kb (as defined by STELA), and the range of telomere 
lengths in our long and short telomere groups would suggest that telomere fusions would be 
expected to occur predominantly in the latter group. 14 The risk of progression was increased 
2-fold for the intermediate group (HR: 2.07, 95% CI: 1.52-2.82, p<0.001) and by 2.7 times 
for the short group (HR: 2.67, 95% CI: 2.03-3.53, p<0.001) when compared to the long 
group while the risk for OS was increased 2.3 and 3.5 times for the intermediate and short 
groups respectively (Table S3 and Fig S4). The median PFS and OS for the 96 patients in the 
long TL group was 4.0 and 9.9 years respectively, and these patients were 63% (HR: 0.37, 
95% CI: 0.28-0.49, p<0.001) and 72% (HR: 0.28, 95% CI: 0.21-0.39, p<0.001) less likely to 
progress or die compared to patients within the short TL group (Table S4).
Further investigations into the genomic and immunogenetic context of the three TL groups 
in 170 CLL4 patients with complete TP53 and ATM deletion and mutational data showed 
that poor-risk features, such as unmutated IGHV genes, TP53 abnormalities, biallelic ATM 
inactivation, and genomic complexity were found at a higher frequencies in the intermediate 
and especially in the short TL groups (Fig 1, Table S5). The short TL group also included 
occasional patients that lacked poor risk biomarkers thus identifying additional patients with 
poor outcome after first-line chemotherapy. Conversely, the long TL group captured patients 
with extended survival despite having poor-risk features. Interestingly in the long TL group, 
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patients with TP53 abnormalities or biallelic ATM inactivation predominantly had mutated 
IGHV genes whereas they were unmutated in the short TL group.
Next, we estimated the adjusted impact of the telomere length categories on PFS and OS 
after controlling for confounding variables using multivariate Cox regression. The short TL 
category, treatment allocation (CHL, FDR, FC), unmutated IGHV genes, the presence of an 
11q deletion and TP53 abnormality emerged as strong predictors of shorter PFS when the 
stepwise backward and forward selection method was employed to arrive at a final model 
(Table 1). The highest increase in risk of progression was for patients with a TP53 
abnormality (HR: 2.51, 95% CI: 1.66 to 3.81, p<0.001) followed by the short group for 
telomere length (short vs long HR: 2.10, 95% CI: 1.37 to 3.21). It is interesting to note that 
short telomere length had a more detrimental effect on progression than unmutated IGHV 
genes or 11q deletion. Shorter telomere length, unmutated IGHV genes and a TP53 
abnormality remained as strong predictors of shorter overall survival as well.
We then used sensitivity-specificity analysis to derive likelihood ratios (LR+ and LR− and 
the LR+/LR− ratio) to judge the relative discriminatory power of each of the four biomarkers 
(TL, IGHV, TP53 and 11q deletion) that were strong predictors of PFS and/or OS in our 
whole cohort, to predict both the presence and absence of PFS and OS events at last follow-
up in the 292 patients with complete TL, IGHV, 11q deletion and TP53 abnormality data 
(Tables S6-S9). One caveat was that LR+/LR− for PFS events could not be estimated for 
TP53 alone as the false negative rates were zero.
The best predictor of PFS events was the combined short and intermediate TL groups (cut-
off <75th percentile), alone (LR+/LR−: 15.54) or in combination with a TP53 abnormality 
(LR+/LR−: 16.35) (Table S6). 81% of patients who progressed or died had short or 
intermediate length telomeres. Consistent with the recursive partitioning data, the best 
predictor of long PFS (absence of PFS events) was the long TL group alone (LR+/LR− : 
15.26) or in combination with wild type TP53 (LR+/LR−: 17.20) (Table S7). Long TL 
correctly predicted the 18/23 patients who did not have a PFS event (sensitivity of 78.3%), 
while 218/269 patients without long TL did have a PFS event during follow-up (specificity 
of 81%). As with the presence of PFS events, the inclusion of IGHV mutational status alone 
or combined with TL and TP53 data did not increase the LR+/LR− ratio further (Table S7). 
For OS, the LR+/LR− for the short TL sub-group was 4.70, with the highest ratio for TP53 
abnormality (LR+/LR−: 8.83), with sensitivity, specificity and accuracy rates of 84.5%, 
51.5% and 77.1%, respectively (Table S8). The long TL category provided a LR+/LR− ratio 
of 5.82 to predict the absence of an OS event, second to TP53 (LR+/LR−: 8.61) but with 
much higher specificity (Table S9). In each case LR ratios were improved for TL in 
combination with IGHV mutational status, TP53 data, or both.
In summary, our data confirm that both MMQ-PCR and STELA can provide clinically 
relevant information in the range of telomere lengths found in CLL. Importantly we 
demonstrate for the first time that TL is superior both to established and to recently 
discovered genomic biomarkers for predicting prolonged PFS following chemotherapy. A 
study of telomere length using MMQ-PCR in 620 patients entered into the CLL8 trial 
currently presented in abstract form only, identified TL as an independent marker of PFS but 
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not OS in models which incorporated a similar range of biomarkers to those employed in our 
study, suggesting that TL also has prognostic significance in patients treated with chemo-
immunotherapy. 15 It remains to be seen whether TL will retain prognostic value in patients 
treated solely with non-genotoxic therapies. Whilst these novel therapies show very 
significant promise, long-term data on side effects and drug resistance are awaited and they 
may be unsuitable or unaffordable for some patients. In contrast, immunochemotherapy can 
offer good long-term outcomes with acceptable toxicity to subgroups of patients with CLL 
14. In conclusion, TL, which usually remains stable on sequential analyses 5 warrants 
further evaluation in CLL patients receiving therapy. Factors such as cost, reproducibility 
and availability will determine the assay method of choice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Kaplan-Meier plots of mean telomere length (from MMQPCR) divided into three groups 
for PFS (A) and OS (B), and distribution of CLL biomarkers within the telomere length groups 
for 170 patients with complete data for TP53 and ATM status (C)
For (A) and (B), Log-rank P-value for each of the lower quartiles when compared to the 
Long group is <0.001. Long: >75 percentile; Intermediate: 50-75 percentile; Short: <50 
percentile. The median PFS and OS for the 96 patients in the long TL group was 4.0 and 9.9 
years respectively. This longer median survival was sustained when the analyses were 
performed with similarly categorised TL groups using measurements from both MMQPCR 
and STELA in the 111 patients with data for both (PFS: 8.1 and 5.1 years; OS: not reached 
and 9.8 years, Fig S5 and 6). For (C) data are presented in decreasing telomere length as 
measured by MMQPCR and divided into the three groups as described in the text. LONG: 
>75 percentile, INTERMEDIATE: 50-75 percentile, SHORT: <50 percentile. Each short 
vertical line (below the TL group name) corresponds to a patient. The presence and absence 
of each of the biomarker status listed on the left are represented by black and grey boxes 
respectively whereas white boxes indicate missing data on the biomarker status. *ZAP70 is 
expressed if >10%-positive cells by flow-cytometry, #CD38 is expressed if >7%-positive 
cells by flow-cytometry, ¶Beta- M: beta-2 microglobulin (present: >4 mg/L), ¥Present: if: >3 
deletions/changes per patient.
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Table 1
Predictors of overall and progression-free survival
Factor HR (95% CI) P-value
PFS
Male vs female 1.34 (0.999 to 1.80) 0.05
Treatment <0.001
 Fludarabine vs. chlorambucil 0.72 (0.52 to 0.996) 0.047
 (Fludarabine + cyclophosphamide) vs. chlorambucil 0.38 (0.28 to 0.50) <0.001
Telomere length <0.001
 Intermediate vs. Long 1.31 (0.83 to 2.05) 0.246
 Short vs. Long 2.10 (1.37 to 3.21) 0.001
IGHV unmutated vs. mutated 1.59 (1.12 to 2.25) 0.01
TP53 abnormal vs. normal 2.51 (1.66 to 3.81) <0.001
11q deleted vs. not deleted 1.46 (1.07 to 1.98) 0.02
OS
Telomere length 0.003
 Intermediate vs. Long 1.34 (0.72 to 2.46) 0.355
 Short vs. Long 2.21 (1.27 to 3.87) 0.005
IGHV unmutated vs. mutated 2.08 (1.22 to 3.57 0.01
TP53 abnormal vs. normal 2.11 (1.26 to 3.53) 0.004
ZAP70 expressed vs. not expressed§ 0.65 (0.45 to 0.96) 0.03
13q deleted vs. not deleted 0.67 (0.47 to 0.95) 0.02
Telomere length groups: Long: >75 percentile; Intermediate: 50-75 percentile; Short: <50 percentile. Candidates entered in the iterative backward-
forward selection method were factors with P-values ≤0.05 in the univariable analysis (see Figure S4). Age was entered as a continuous variable for 
the multivariable analysis.There was a small but significant negative association between age and shorter TL (data not included). The final models 
were based on 292 subjects and 269 events for PFS and 201 subjects and 153 deaths for OS.
§
expressed if expression levels >10%
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